BRITISH COLUMBIA, Canada, September 9 /PRNewswire/ --
InNexus Biotechnology Inc., (TSX: IXS.V, OTC Bulletin Board: IXSBF, http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, welcomes David Warden to its Board of Directors.
Mr. Warden was a founding partner of Yetter, Warden & Coleman, L.L.P. In his 23 years of practice, he has represented both plaintiffs and defendants in cases pertaining to antitrust, securities violations, trade secrets, patents, and other business and technology litigation.
"I am pleased to have David join our team as a director on our Board," said Jeff Morhet, Chairman and CEO. "His broad legal experience and, in particular, his expertise in patent law will prove valuable as we continue to expand and fortify our intellectual property position. I look forward to working with David as a valuable addition to our Board."
Mr. Warden is considered one of Houston's top Lawyers from H magazine and recognized as one of the Texas "Super Lawyers" in Texas Monthly magazine from 2003-2006. Warden has published many articles during his career, "Trade Secrets and Patents: Comparison and Contrasts in Royalty Determination," and "How to Quantify Trade Secrets Theft," are among them. He received his B.S. and his M.S. in Engineering from Purdue University and obtained his Juris Doctorate degree in 1981 from the University of Virginia.
InNexus has taken deliberate steps to enhance its intellectual property position. This latest addition follows a previous appointment of Gilbert Gabo, as the company's Vice President of Operations and Director of Legal Affairs. Mr. Gabo was a practicing patent attorney with the law firm of Gifford, Krass, Sprinkle, Anderson & Citkowski, P.C. before joining the company and also brings a decade of operations experience from his work as a product engineer. He received his J.D. in 2001 from the University of Detroit Mercy Law School and his B.S. in Engineering in 1993 from the University of Michigan in Ann Arbor.
About InNexus
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.
Web site: http://www.ixsbio.com
Jeff Morhet, Chairman & Chief Executive Officer of InNexus Biotechnology Inc., +1-480-862-7500
Comments